Efectividad del tratamiento con ciprofloxacino durante 21 días en la primoinfección por pseudomonas aeruginosa en las bronquiectasias no fibrosis quística / Effectiveness of treatment with ciprofloxacin during 21 days in primoinfection by pseudomonas aeruginosa in the bronchiectasia not cystic fibrosis

Las bronquiectasias no debidas a fibrosis quística (FQ) constituyen la tercera patología inflamatoria crónica más frecuente de las vías respiratorias.La infección bronquial determina la progresión de la enfermedad, siendo la infección por Pseudomonas aeruginosa la que se asocia con peor pronóstico. Por este motivo, las guías de práctica clínica recomiendan la erradicación de P. aeruginosa en la infección primaria. Hasta el momento ningún estudio ha demostrado la utilidad real de esta pauta de tratamiento en el manejo de la infección bronquial inicial por Pseudomonas aeruginosa, por lo que el objetivo de este estudio es determinar la efectividad del tratamiento con Ciprofloxacino 750 mg cada 12 horas por vía oral durante 21 días en la erradicación de P. aeruginosa en pacientes con bronquiectasias no relacionadas con FQ. (AU)

Bronchiectasis not due to cystic fibrosis (CF) constitutes the third most frequent chronic inflammatory pathology of the airways. Bronchial infection determines the progression of the disease, being infection by Pseudomonas aeruginosa the one that is associated with the worst prognosis. For this reason, clinical practice guidelinesrecommend eradication of P. aeruginosa in primary infection. At the moment, any study has shown the real usefulness of this treatment regimen in the management of the initial bronchial infection by Pseudomonas aeruginosa, so the objective of this study is to determine the effectiveness of treatment with Ciprofloxacin 750 mg every 12 hours orally for 21 days in the eradication of P. aeruginosa in patients with non-CF bronchiectasis. (AU)

Exceptional Case of Endobronchial Foreign Body Mimicking Primitive Lung Cancer

No disponible

Unusual Coexistence: Double Superior Vena Cava and Bronchial Atresia / Una coincidencia infrecuente: doble vena cava superior y atresia bronquial

No disponible

Evolución de los ingresos por bronquiectasias en un hospital de tercer nivel (2008-2017) / Trends in Admission for Bronchiectasis in a Third-Level Hospital (2008-2017)

No disponible

Deterioro clínico por Exophiala dermatitidis en un paciente con fibrosis quística / Clinical Deterioration Due to Exophiala Dermatitidis in a Patient with Cystic Fibrosis

No disponible

Atresia bronquial diagnosticada incidentalmente tras traumatismo torácico / Incidental diagnosis of bronchial atresia after chest trauma

No disponible

Traqueobroncopatía osteocodroplástica. Causa de hemoptisis en paciente joven / Osteocodroplastic tracheobroncopathy. Cause of hemoptisis in a young patient

Describimos el caso de un varón de raza caucásica de 42 años que acude a Urgencias por hemoptisis sin repercusión hemodinámica. El paciente no refiere ningún antecedente de interés. Se le realiza angio-tomografía computarizada (angioTC) , la cual descarta tromboembolismo pulmonar y punto de sangrado activo. El paciente es ingresado para completar estudio y vigilancia. Se descartan causas infecciosas y vasculares de la hemoptisis, por lo que tras un nuevo episodio de hemoptisis se decide trasladar a la UCI. Tras dos fibrobroncoscopias, donde se aprecia una mucosa en empedrado del árbol traqueobronquial y tras la toma de biopsias, se concluye que el diagnóstico es compatible con traqueobroncopatía osteocondroplástica

We describe the case of a 42-year-old caucasian male who went to the Emergency room for hemoptysis without hemodynamic repercussion. The patient does not refer any antecedent of interest. Angio-computerized tomography (angioCT) is performed, which rules out pulmonary thromboembolism and active bleeding point. The patient is admitted to complete study and surveillance. Infectious and vascular causes of hemoptysis are ruled out, so after a new episode of hemoptisis, it is decided to move to the ICU. After two fibrobronchoscopies, showing a cobblestone mucosa of the tracheobronchial tree and after taking biopsies, it is concluded that the diagnosis is compatible with osteochondroplastic tracheobronchopathy

Papel de los estudios de imagen en el diagnóstico etiológico de las bronquiectasias: la distribución es la clave / The role of imaging in the diagnosis of bronchiectasis: the key is in the distribution

La patología de las vías respiratorias de medio calibre (bronquios segmentarios y subsegmentarios) es común y se presenta con síntomas respiratorios poco específicos, como tos, infecciones de repetición y en ocasiones hemoptisis. La dilatación permanente del árbol bronquial se conoce como «bronquiectasia» y representa un reto diagnóstico. El análisis de la distribución regional de las bronquiectasias en los diferentes lóbulos pulmonares es la guía diagnóstica más útil. El objetivo de este trabajo es describir los hallazgos de imagen de las bronquiectasias y sus diferentes tipos, revisar las situaciones más comunes y proponer un algoritmo diagnóstico basado en su distribución anatómica. Las bronquiectasias son un hallazgo frecuente, resultado de un amplio espectro de enfermedades. Los estudios de imagen desempeñan un papel esencial en su detección, clasificación y orientación diagnóstica hacia la patología subyacente (AU)

Diseases that involve the medium caliber airways (segmental and subsegmental bronchi) are common and present clinically with nonspecific respiratory symptoms such as cough, recurrent respiratory infections and occasionally, hemoptysis. The abnormal and irreversible dilation of bronchi is known as "bronchiectasis". The diagnosis can be challenging and the analysis of the regional distribution of the bronchiectasis is the most useful diagnostic guide. The objective of this manuscript is to describe the main imaging findings of bronchiectasis and their classification, review the diseases that most commonly present with this abnormality, and provide an approach to the diagnosis based on their imaging appearance and anatomic distribution. Bronchiectasis is a frequent finding that may result from a broad range of disorders. Imaging plays a paramount role in diagnosis, both in the detection and classification, and in the diagnosis of the underlying pathology (AU)

Exhaled nitric oxide in relation to asthma control: A real-life survey

BACKGROUND: Asthma is characterised by chronic airway inflammation, a complex cascade of events, mostly sustained by eosinophil recruitment and activation. Fractional exhaled nitric oxide (FeNO) is a surrogate marker of airway inflammation closely associated with bronchial eosinophilia. FeNO is used to define asthma phenotype, to assess eosinophilic inflammatory severity and to predict corticosteroid responsiveness. OBJECTIVE: The aim of this study was to investigate whether FeNO may be associated with some clinical and functional factors in asthmatics evaluated in a real life setting. METHODS: Globally 363 patients (150 males, mean age 46.3 years) with asthma were consecutively evaluated. The following parameters were assessed: history, including comorbidities, physical examination, body mass index (BMI), lung function, asthma control grade, asthma control test (ACT), and FeNO. RESULTS: FeNO values were significantly higher in patients with poorly controlled asthma (p < 0.01), asthma symptoms (p = 0.015), wheezing (p < 0.001), rhinitis diagnosis, (p = 0.049) and rhinitis symptoms (p = 0.019), but lower in patients with GERD (p = 0.024) and pneumonia history (p = 0.048). FeNO values increased in patients with the lowest corticosteroid dose (p = 0.031). FeNO values > 25 ppb were associated with poorly controlled asthma (OR 3.71), asthma signs (OR 3.5) and symptoms (OR 1.79). A FeNO value cut-off of 29.9 ppb was fairly predictive of (AUC 0.7) poorly controlled asthma. CONCLUSIONS: FeNO assessment in clinical practice may be a useful tool for monitoring asthmatics as it is associated with several clinical factors, including asthma control

No disponible